Amalgamated Bank lifted its holdings in shares of Bioverativ Inc (NASDAQ:BIVV) by 5.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 22,800 shares of the biotechnology company’s stock after acquiring an additional 1,205 shares during the quarter. Amalgamated Bank’s holdings in Bioverativ were worth $1,229,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in BIVV. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Bioverativ during the fourth quarter worth about $105,000. American Assets Investment Management LLC purchased a new stake in shares of Bioverativ during the fourth quarter worth about $108,000. Advisors Asset Management Inc. purchased a new stake in shares of Bioverativ during the third quarter worth about $137,000. Ladenburg Thalmann Financial Services Inc. purchased a new stake in shares of Bioverativ during the third quarter worth about $190,000. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Bioverativ during the third quarter worth about $194,000. 97.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of Bioverativ Inc (NASDAQ:BIVV) opened at $104.98 on Tuesday. The firm has a market capitalization of $11,360.00 and a PE ratio of 38.31. Bioverativ Inc has a fifty-two week low of $48.14 and a fifty-two week high of $105.01.
A number of analysts have recently issued reports on BIVV shares. William Blair reaffirmed a “hold” rating on shares of Bioverativ in a research report on Thursday, March 8th. Royal Bank of Canada lifted their target price on Bioverativ to $68.00 and gave the stock a “market perform” rating in a research report on Thursday, January 18th. Zacks Investment Research raised Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a research report on Monday, January 1st. Jefferies Group lifted their target price on Bioverativ to $79.00 and gave the stock a “buy” rating in a research report on Thursday, January 18th. Finally, Raymond James Financial lowered Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. Thirteen research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $63.15.
TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/03/13/amalgamated-bank-has-1-23-million-stake-in-bioverativ-inc-bivv.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.